OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 00:07 UTC. Every row links to its source record.

BCL11B BCL11 transcription factor B

ENSG00000127152 · protein coding · Open Targets profile

Key regulator of both differentiation and survival of T- lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of hematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus (PubMed:27959755). Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4(+) T-lymphocytes (PubMed:16809611). Tumor-suppressor that represses transcription through direct, TFCOUP2-independent binding to a GC-rich response element (By similarity). May also function in the P53-signaling pathway (By similarity). {ECO:0000250|UniProtKB:Q99PV8, ECO:0000269|PubMed:16809611, ECO:0000269|PubMed:27959755}.

In 15 of 15 cancers, the evidence for BCL11B comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751T-cell acute lymphoblastic leukemiaT-cell acute lymphoblastic leukemiaT-cell acute lymphoblastic leukemia: somatic 0.61lung carcinomalung carcinomalung carcinoma: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61skin carcinomaskin carcinomaskin carcinoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61colon adenocarcinomacolon adenocarcinomacolon adenocarcinoma: somatic 0.46colon adenocarcinoma: germline 0.32diffuse large B-cell lymphomadiffuse large B-cell lymphomadiffuse large B-cell lymphoma: somatic 0.41hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46adult T-cell leukemia/lymphomaadult T-cell leukemia/lymphomaadult T-cell leukemia/lymphoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.16046999394893646 (upper bound 0.2895500063896179). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of BCL11B's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of BCL11B's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.